Bryan Johnson's ongoing relationship with Blueprint co-founder Kate Tolo, publicly confirmed in late 2025, remains the core driver of trader sentiment on intimacy timelines. He has detailed their sexual activity through biomarker tracking—such as post-intimacy shifts in prolactin, oxytocin, and vagal tone—while treating nighttime erections and sexual function as Tier-1 longevity metrics alongside VO2 max and HRV. Recent August 2026 updates emphasize separate beds and homes to protect sleep quality, yet affirm that intimacy occurs and is measured rigorously under his Blueprint protocol. This data-centric approach, including microbiome scoring and protocol optimizations like daily tadalafil, creates a transparent but highly regimented framework where any public announcement of activity could swiftly shift implied probabilities. Key near-term catalysts include routine health updates or conference appearances that might prompt further disclosures.